Decitabine (NSC 127716)

For research use only. Not for use in humans.

製品コードS1200 別名:Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR

Decitabine (NSC 127716)化学構造

CAS No. 2353-33-5

Decitabine (NSC 127716, Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine, 5-AZA-dC, 5-aza-CdR) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.

サイズ 価格(税別)  
10mM (1mL in DMSO) JPY 27700
JPY 16900
JPY 30200
JPY 55100
JPY 96600
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(107)

製品安全説明書

DNA Methyltransferase阻害剤の選択性比較

生物活性

製品説明 Decitabine (NSC 127716, Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine, 5-AZA-dC, 5-aza-CdR) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.
ターゲット
DNA methylation [1]
(HL-60, KG1a cells)
体外試験

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 MU\GeY5kfGmxbjDBd5NigQ>? M3HKSlAvPcLizszN MoqyNlQhcA>? MoPLe4F1\XJ? NHH0[Yxud2S3bHH0[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDNRWdGNUFibXXtZoVzew>? NYHRdHRmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlMxQDJpPkK1NVI{ODh{PD;hQi=>
Eca109 M3G4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXIN2xKOC53L{KuOU82KM7:TR?= M1LR[lI1NzR6L{eyJIg> NVrZ[GR1f2G2ZYK= MYPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJIRwe2VvIHHu[EB1cW2nLTDk[ZBmdmSnboSgcYFvdmW{ NXLCTHZmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlMxQDJpPkK1NVI{ODh{PD;hQi=>
Eca109 NXvOclgyTnWwY4Tpc44hSXO|YYm= MVOwMlXDqM7:TR?= NInlcm43NzF{L{K0JIg> NVu4VlNYf2G2ZYK= M{nHRolvcGmkaYTzJINmdGxibXnndoF1cW:wwrC= MnvZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
Eca109 M4TKdmZ2dmO2aX;uJGF{e2G7 M4G3VlAvPcLizszN NVnFb2RuOjRiaB?= NHjybHB4[XSnch?= MV7pcohq[mm2czDj[YxtKGmwdnHzbY9v NUDNU3p6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlMxQDJpPkK1NVI{ODh{PD;hQi=>
Eca109 M{fVemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[5O2ExOC53wrFOwG0> NV7ZdZFiOjRiaB?= NEns[Hd4[XSnch?= M2XMZYlv\HWlZYOgS|IwVSCjcoLld5QhcW5idHjlJINmdGxiY4njcIU> M3TRUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUKzNFgzLz5{NUGyN|A5OjxxYU6=
Eca109 Ml2ySpVv[3Srb36gRZN{[Xl? MYqwMlUwOSEQvF2= NXrMOWc4OjRiaB?= NIj3blV4[XSnch?= NGrlfHdl\WO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDOSk3PwkJ{IHHu[EBOVVB{ NF;MN4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyN|A5Oid-MkWxNlMxQDJ:L3G+
SW1116  M{\DXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnsc4R7OC53L{GvNk82KM7:TR?= NGXpS3I1QCCq MWPEUXNQ MUnlcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u NHnKcIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3OFI5Pid-MkS4O|QzQDZ:L3G+
LOVO NVLnT45FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY[wMlUwOS9{L{Wg{txO Mor6OFghcA>? NVHOZ4x1TE2VTx?= MVzlcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u NEjXdGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3OFI5Pid-MkS4O|QzQDZ:L3G+
SW1116  MlrwSpVv[3Srb36gRZN{[Xl? M4TFfVExKM7:TR?= Mlu2OFghcA>? NE\QbG9FVVOR M4fFXolv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>? NEW1[mk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3OFI5Pid-MkS4O|QzQDZ:L3G+
LOVO NX6xZpFCTnWwY4Tpc44hSXO|YYm= M4T4ZVExKM7:TR?= NHLqdG81QCCq M3TYSGROW09? MnPSbY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
SW1116  MmDpRZBweHSxc3nzJGF{e2G7 MX[xNEDPxE1? NX3RNGc6PDhiaB?= NXvFdJRmTE2VTx?= MUjlcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:|aYO= NVjZW3BxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|QzQDZpPkK0PFc1Ojh4PD;hQi=>
LOVO NIrNe5hCeG:ydH;zbZMhSXO|YYm= NYjoeplqOTBizszN MUG0PEBp NEXuTFBFVVOR MnrT[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
RPMI-8226 NXLiUot6SXCxcITvd4l{KEG|c3H5 MVqxM|Ih|ryP MXW0PE84Oi97NjDo NX7Fe5FnTE2VTx?= NHe4VJdqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|M{GwPEc,OjR6M{OxNFg9N2F-
OPM-2  MoDTRZBweHSxc3nzJGF{e2G7 MVSxM|Ih|ryP NFfOTYQ4Oi97Nj:xNlAhcA>? NWPL[5FRTE2VTx?= NUHjUpd3cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M13CSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN|ExQDxxYU6=
JJN3  NVW4SWRVSXCxcITvd4l{KEG|c3H5 MUCwMlUwOSEQvF2= M1HQNFI1NzR6IHi= NFzFbohFVVOR NGfmd|NqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|M{GwPEc,OjR6M{OxNFg9N2F-
NCI-H929  NWS3XVFDSXCxcITvd4l{KEG|c3H5 NHHU[pEyNzJizszN M2W5RlczNzl4L{GyNEBp NIfnVGxFVVOR NIfhb3hqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|M{GwPEc,OjR6M{OxNFg9N2F-
RPMI-8226 MoXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDudGwyNzJizszN MWWyOE81QC95MjDo NX\HVlNmTE2VTx?= M4Pse4Fn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 NVTxU|hWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|MyODhpPkK0PFM{OTB6PD;hQi=>
OPM-2  MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYSxM|Ih|ryP NHTNfpYzPC92OD:3NkBp MkTRSG1UVw>? NV;ZV|Fx[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|M{GwPEc,OjR6M{OxNFg9N2F-
JJN3  NYnUT4RZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;2NE42NzFizszN NHjXVoMzPC92OD:3NkBp NFfl[2hFVVOR NUe2cm91[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= NFH1[WU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizN|ExQCd-MkS4N|MyODh:L3G+
NCI-H929  MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfrNU8zKM7:TR?= NGK1T3MzPC92OD:3NkBp MYHEUXNQ NVy0SVhV[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= M1zIclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN|ExQDxxYU6=
HeLa NVHMZZdIU2mwYYPlJGF{e2G7 NG[5eoZMcT1zMECw5qCUPTByMDFOwG0h\m:{IHjFUnQy NGq5[YI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4NFA6QCd-MkS3PFAxQTh:L3G+
HeLa MVLLbY5ie2ViQYPzZZk> M2e1XmtqRTVwNjFCtUAxNjVizszNJIZweiCqRV7UNi=> NXnwU4R5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFAxQThpPkK0O|gxODl6PD;hQi=>
HeLa M1;6d2tqdmG|ZTDBd5NigQ>? MnLIT4k:OjFwNjFCtUA{NjBizszNJIZweiCqQ17UNS=> NGXZZYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4NFA6QCd-MkS3PFAxQTh:L3G+
HeLa MV7LbY5ie2ViQYPzZZk> MljuT4k:OTRwNDFCtUA1NjZizszNJIZweiCqQ17UNy=> Mm\uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OECwPVgoRjJ2N{iwNFk5RC:jPh?=
NB4 MXzGeY5kfGmxbjDBd5NigQ>? NYjKXZdvOi53L{WvO{42NzFyIN88US=> NYTvd4xqOjRiaB?= Mn;lSG1UVw>? NVzsfWd{cW6lcnXhd4ViKHSqZTDlfJBz\XO|aX;uJI9nKHC{ZXP1dpNweiCvaWKtNVI2[Q>? NX\lOYVNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PFQ5PzBpPkK0OFg1QDdyPD;hQi=>
CD4+ CD25− T  MX\GeY5kfGmxbjDBd5NigQ>? M1\vT|EwPSEQvF2= NWniRVlremWmdXPlV{BodG:kYXygSG5CKG2ndHj5cIF1cW:w NYm4XJZ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O|Y{PjBpPkK0OFc3OzZyPD;hQi=>
BV-173 NVfCdZVZSXCxcITvd4l{KEG|c3H5 MofjNE4zPS9yLkWvNE44PS9zIN88US=> NWezUnpEPDhxN{KvPVYhcA>? NIW0VpPDqFCEUx?= MVTpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= NGnHbWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN|YyOyd-MkS0NlM3OTN:L3G+
ML-1 MVzBdI9xfG:|aYOgRZN{[Xl? NETtXFIxNjJ3L{CuOU8xNjd3L{Gg{txO NUPw[W1FPDhxN{KvPVYhcA>? M1zKceKhWEKV MlHkbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
HL-60 Mn;mRZBweHSxc3nzJGF{e2G7 MYCwMlI2NzBwNT:wMlc2NzFizszN MnjFOFgwPzJxOU[gbC=> NETPTnXDqFCEUx?= NGTk[3dqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NXTiVopyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF|PD;hQi=>
KG-1a NFnXS|ZCeG:ydH;zbZMhSXO|YYm= NHviOFMxNjJ3L{CuOU8xNjd3L{Gg{txO NGrpeFQ1QC95Mj:5OkBp MVZCpHBDWw>? NFzWTnJqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> MlTVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkO2NVMoRjJ2NEKzOlE{RC:jPh?=
BV-173 M1nNOWZ2dmO2aX;uJGF{e2G7 MVyyOVAwPTBybl2= NG\qNpM1QCCq NX3WXJVRyqCSQmO= Mn3EbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MnfwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkO2NVMoRjJ2NEKzOlE{RC:jPh?=
CEM M4XU[mZ2dmO2aX;uJGF{e2G7 M1;LcVI2OC93MEDuUS=> MoTCOFghcA>? Mn3BxsBRSlN? MlPVbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn M1[zS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN|YyOzxxYU6=
HL-60 Ml7qSpVv[3Srb36gRZN{[Xl? NFXqNHYzPTBxNUCwcm0> NYXpcHVEPDhiaB?= MUJCpHBDWw>? MVfpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? MnPqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkO2NVMoRjJ2NEKzOlE{RC:jPh?=
ML-1 NF3DXXVHfW6ldHnvckBCe3OjeR?= Ml:0NlUxNzVyMH7N MlrTOFghcA>? MV1CpHBDWw>? Ml3PbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MknPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkO2NVMoRjJ2NEKzOlE{RC:jPh?=
DLD-1 Mn3ESpVv[3Srb36gRZN{[Xl? MVWyOVAwPTBybl2= NEXp[2E1QCCq MkS2xsBRSlN? M2DENYRwKG6xdDDpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NILtWGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN|YyOyd-MkS0NlM3OTN:L3G+
HCT-116 Mo\VSpVv[3Srb36gRZN{[Xl? NXm0[phvOjVyL{WwNI5O M1\uZlQ5KGh? NHLUcZjDqFCEUx?= MXnkc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm MoHqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkO2NVMoRjJ2NEKzOlE{RC:jPh?=
U937-A/E-9/14/18  M3LIRWFxd3C2b4Ppd{BCe3OjeR?= NXvCR4dPOC5yMT:wMlEwOS9zMDFOwG0> MkniOFghcA>? NHLEd2ZqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDNyMES1Okc,OjR|MEC0OVY9N2F-
HT29 M3;Vb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYG3NkBp Mn3pTWM2OD1zNECwxtEyPzlizszN MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF5MkC2NUc,OjRzN{KwOlE9N2F-
SW48 NIPlZ5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnSdJQzPzJiaB?= MWTJR|UxRTF3LkNCtVYvOiEQvF2= MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF5MkC2NUc,OjRzN{KwOlE9N2F-
HCT116 Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXuW2RuPzJiaB?= NVXvWYVFUUN3ME2xMlfDuTBwNDFOwG0> MkDvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzN{KwOlEoRjJ2MUeyNFYyRC:jPh?=
HepG2 NInUeIVHfW6ldHnvckBCe3OjeR?= NEjl[HgxNjVxMTFOwG0> NGrON5EzPCCq Mm\pSG1UVw>? MlLueZAuemWpdXzheIVlKHSqZTDy[YxifGm4ZTDPR3RPOiCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? MnnpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNE[4O|QoRjJ2MUS2PFc1RC:jPh?=
LS174T M2iwXWZ2dmO2aX;uJGF{e2G7 NH\IXJExNjVxMTFOwG0> MkHJNlQhcA>? MoD0SG1UVw>? MUfs[YFlKHSxIHHuJIlv[3KnYYPlJI9nKE:FVF6yJIxmfmWucx?= MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF2Nki3OEc,OjRzNE[4O|Q9N2F-
HepG2 M1XP[mFxd3C2b4Ppd{BCe3OjeR?= MWexM|ExNzFyMDFOwG0> NX2y[4s5PyCm NULH[mlFTE2VTx?= Mlm4bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MmfkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNE[4O|QoRjJ2MUS2PFc1RC:jPh?=
LS174T NWLFZ2JoSXCxcITvd4l{KEG|c3H5 MYKxM|ExNzFyMDFOwG0> MnzwO{Bl NVPrZmFCTE2VTx?= M2DCZolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXfac25rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFY5PzRpPkK0NVQ3QDd2PD;hQi=>
QBC-939 NUf1WVZrSXCxcITvd4l{KEG|c3H5 NUDRe5V4OS9zMD:xNFAh|ryP M1fCVVch\A>? MX;EUXNQ MV\pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmLRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNE[4O|QoRjJ2MUS2PFc1RC:jPh?=
U251 MXfBdI9xfG:|aYOgRZN{[Xl? NGrMdYoyNzFyL{GwNEDPxE1? MnG4O{Bl M4j1XmROW09? MmHPbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF2Nki3OEc,OjRzNE[4O|Q9N2F-
HL-60 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vsflEh|ryP MXy0PEBp M4HwS4lv[3KnYYPld{BIOi2yaHHz[UBk\WyuIH\yZYN1cW:w MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDByMEOyOEc,OjRyMECzNlQ9N2F-
MDA‑MB‑453 M2PaRmZ2dmO2aX;uJGF{e2G7 MUiwMlIwOSEQvF2= M{i2SFczKGh? NV3wSG4z[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NEKyPEc,OjN6NESyNlg9N2F-
HCC1569 MXPGeY5kfGmxbjDBd5NigQ>? NIW5VJoxNjJxMTFOwG0> NGDleoI4OiCq NGTQdWJk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> NGfGXGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFIzQCd-MkO4OFQzOjh:L3G+
BT‑474 MYnGeY5kfGmxbjDBd5NigQ>? NHrYT3MxNjJxMTFOwG0> NHTz[Ho4OiCq NGSwZoRk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> MnrmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESyNlgoRjJ|OES0NlI5RC:jPh?=
AGS NGqweINCeG:ydH;zbZMhSXO|YYm= MmftOU8yOC9{MD:1NEDPxE1? Mlu5OFjDqGkEoB?= NEDsV4dFVVOR NXHKOWY4cW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6yqB? M33lOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUiyO|g1Lz5{M{W4Nlc5PDxxYU6=
A549 Mo[3RZBweHSxc3nzJGF{e2G7 M2fqTVUwOTBxMkCvOVAh|ryP MWm0POKhcMLi Mm\kSG1UVw>? M2jpT4lvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh M4HsPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUiyO|g1Lz5{M{W4Nlc5PDxxYU6=
AGS  MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7QRXc2NzFyL{KwM|UxKM7:TR?= M{GybFQ5yqCqwrC= Ml34SG1UVw>? MX\pcoR2[2W|IFeyM20heGijc3WgZZJz\XO2wrC= MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV6Mke4OEc,OjN3OEK3PFQ9N2F-
Kasumi-1 MV3BdI9xfG:|aYOgRZN{[Xl? NW\5dphrOC53IN88US=> M1PDZ|Q5yqCqwrC= NYjPe4o{\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7M{O0PEc,OjN2OUOzOFg9N2F-
OCI-AML3 MnTCRZBweHSxc3nzJGF{e2G7 MYCyMlUh|ryP NVPXe2RZPDkEoHlCpC=> MX3k[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7M{O0PEc,OjN2OUOzOFg9N2F-
MV4-11 NIrj[mNCeG:ydH;zbZMhSXO|YYm= M4\GNlIvPSEQvF2= NUjzenBuPDkEoHlCpC=> MYnk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7M{O0PEc,OjN2OUOzOFg9N2F-
NK  NHTVfG5EgXSxdH;4bZR6KEG|c3H5 MUmwMlAzNTJyIN88US=> NIrnblc2KGR? MYrk[YNz\WG|ZYOgeIhmKGO7dH;sfZRq[yCjY4Tpeol1gSCxZjDOT{Bk\WyuczDheEBqdnSncn3l[IlifGViY3;uZ4VvfHKjdHnvcpMhemW|dXz0bY5oKGmwIHGgWU1{cGGyZXSg[I9{\eLCk4Lld5BwdnOnIHP1dpZm NFm5NVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OyPFA5QCd-MkOzNlgxQDh:L3G+
NK  NIHZemJCeG:ydH;zbZMhSXO|YYm= MUGwMlAzNTJyIN88US=> NWD3Omd7PSCm Ml3s[IVkemWjc3WgUmsh[2WubDDwdo9tcW[ncnH0bY9vKGGwZDD2bYFjcWyrdImgZZMhfGinIHPvcoNmdnS{YYTpc44hcW6lcnXhd4Vl MkLSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MkiwPFgoRjJ|M{K4NFg5RC:jPh?=
NK  MmjKSpVv[3Srb36gRZN{[Xl? MmDSNE4xOS1{MDFOwG0> MVu1JIQ> MnHuZ4F2e2W|IHj5dI9u\XSqeXzheIlwdiCxZjDOT{Bk\WyuczDpckBiKGSxc3ZihLNz\XOyb37z[S=> MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN{OEC4PEc,OjN|MkiwPFg9N2F-
MOLT4/DNR NYizeGZXTnWwY4Tpc44hSXO|YYm= MmG4OUDPxE1? NUjiXJAyPCCm MWTy[YR2[2W|IFHCR2IyKG2UTlGg[ZhxemW|c3nvci=> MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4MEW3NEc,OjNyNkC1O|A9N2F-
Jurkat/DOX M{PJOWZ2dmO2aX;uJGF{e2G7 MVi1JO69VQ>? NYDuWnc6PCCm NX\QNHlsemWmdXPld{BCSkOEMTDtVm5CKGW6cILld5Nqd25? M4jVUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|ME[wOVcxLz5{M{C2NFU4ODxxYU6=
MOLT4/DNR NYDPcIExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzGeoc2KM7:TR?= Mm\UOEBl M4jlTJJm\HWlZYOgeIhmKEmFNUFCpJZidHWnIH\vdkBl[XWwb4L1ZolkcW5ic3Xud4l1cX[rdIm= NV3BcFNIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlA2PzBpPkKzNFYxPTdyPD;hQi=>
Jurkat/DOX MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTFWY1YPSEQvF2= M{nCclQh\A>? MoPSdoVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC|ZX7zbZRqfmm2eR?= NFHSfIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2NFU4OCd-MkOwOlA2PzB:L3G+
ccRCC  MorMRZBweHSxc3nzJGF{e2G7 NYTMTYNKOC5yMT2xNO69VQ>? MYW3NkBp MX3EUXNQ M2ryc4hieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25? NGnXcJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyOlQ3Pyd-MkK4NlY1Pjd:L3G+
TNBC  MkfRRZBweHSxc3nzJGF{e2G7 NWLPT2trOC5yMT2xNO69VQ>? M4PGRVczKGh? NXLXZZk3TE2VTx?= MYHoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v NUPxZZljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NlY1PjdpPkKyPFI3PDZ5PD;hQi=>
A498 NIHNe2NCeG:ydH;zbZMhSXO|YYm= M4\Re|AvODFvMUFOwG0> M3S5TFczKGh? M2DoPGROW09? MmHTbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> NWLEXopkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NlY1PjdpPkKyPFI3PDZ5PD;hQi=>
KIJ265T NFTHRpBCeG:ydH;zbZMhSXO|YYm= M1vuZlAvODFvMUFOwG0> NI\wN|c4OiCq MXzEUXNQ NWjDc4locW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? NYH4NpJuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NlY1PjdpPkKyPFI3PDZ5PD;hQi=>
MDA-231 M33wUmFxd3C2b4Ppd{BCe3OjeR?= MnvoNE4xOS1zMN88US=> NHjxNnQ4OiCq M3HqWmROW09? Mk[0bY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> NWrpb4d3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NlY1PjdpPkKyPFI3PDZ5PD;hQi=>
BT-20 NH\0bFZCeG:ydH;zbZMhSXO|YYm= M2S2dFAvODFvMUFOwG0> MnvPO|IhcA>? NWjHU3U2TE2VTx?= M1zIc4lv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{NkS2O{c,OjJ6Mk[0Olc9N2F-
U937 M3zYbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHUcIs2NTJyIN88US=> NXrLS3JiOjRxNEivO|IhcA>? NVPXR3UxcW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd4N{CyNUc,OjJ5NkewNlE9N2F-
HL60 NIjL[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUW1MVIxKM7:TR?= MlzNNlQwPDhxN{KgbC=> MXjpcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy NHv4cnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke2O|AzOSd-MkK3OlcxOjF:L3G+
U937 NFj3[3pCeG:ydH;zbZMhSXO|YYm= NXjz[I9nOTVizszN NYfofXBROjRxNEivO|IhcA>? NEjZSo5qdmS3Y3XzJINmdGxiYYDvdJRwe2m| NWTjfYtqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3OlcxOjFpPkKyO|Y4ODJzPD;hQi=>
HL60 M2HmNWFxd3C2b4Ppd{BCe3OjeR?= NHLq[IUyPSEQvF2= NE\oW5AzPC92OD:3NkBp MkTMbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M4K1W|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{[3NFIyLz5{Mke2O|AzOTxxYU6=
LS411N  MnHQRZBweHSxc3nzJGF{e2G7 MkXNNE42KM7:TR?= M3;1[lczKGh? MW\pcoNz\WG|ZYOgSoF{KG2UTlGgcIV3\Wx? NV;NSI5URGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0OlE3QTVpPkKyOFYyPjl3PD;hQi=>
MDA-MB-231 Mnn5RZBweHSxc3nzJGF{e2G7 NYHae4dMOTBizszN NX70cGlxPDhiaB?= NVXHOG1FemWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWOxW4hmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4PFc3QTdpPkKxPFg4Pjl5PD;hQi=>
MCF-7  MmD2RZBweHSxc3nzJGF{e2G7 MWexNEDPxE1? MWS0PEBp M1nRW5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MofOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6OEe2PVcoRjJzOEi3Olk4RC:jPh?=
A375 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HUeVAvPSEQvF2= M2nNZVEwPS96IHS= MWrpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? M4CxOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{m2OlIzLz5{MUe5OlYzOjxxYU6=
SKMEL1 MnrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPrU5RTOC53IN88US=> MnnJNU82NzhiZB?= MVfpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? NIHVVIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe5OlYzOid-MkG3PVY3OjJ:L3G+
SKMEL3 MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\iTIkxNjVizszN MWixM|UwQCCm M{fGRolvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| M4n1NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{m2OlIzLz5{MUe5OlYzOjxxYU6=
SKMEL28 NGrNdYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjjN5kxNjVizszN MYWxM|UwQCCm MlvLbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? NEfGN3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe5OlYzOid-MkG3PVY3OjJ:L3G+
MeWo M3uwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HScVAvPSEQvF2= M{P6fVEwPS96IHS= MV;pcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? NYD6THBERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3PVY3OjJpPkKxO|k3PjJ{PD;hQi=>
B16 NUey[FNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVywMlUh|ryP M4L0[lEwPS96IHS= NX:0NZlWcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NEfPUHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe5OlYzOid-MkG3PVY3OjJ:L3G+
Ly 1 NYixc206T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mle3NlQhcA>? MkDlTWM2OD15LkOg{txO M{HZRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 7 M2HIXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vRflI1KGh? NVr0V4xFUUN3ME2xNE44KM7:TR?= M1HNe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Su-DHL6 NV\yNIN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7ib4czPCCq NWXRZpZvUUN3MP-8olIxKM7:TR?= MkOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Ly 10 M3nnN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV6yOEBp NVe5NVkzUUN3MP-8olIxKM7:TR?= M{TZOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
RIVA NVXLR5lVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPo[HUzPCCq NEfQcZZKSzVy78{eNlAh|ryP Ml7ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Su-DHL2 M1LqV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXuydWo{OjRiaB?= MXvJR|Ux97zgMkCg{txO MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Ly 1 NF:0OW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjkOFghcA>? MYLJR|UxRTBwM{Sg{txO M1rTR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 7 NWn2UWd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrOcY81QCCq MnHBTWM2OD1yLkCyOUDPxE1? M2Hu[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Su-DHL6 NUna[|c1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYO0PEBp NWXUdnE6UUN3MP-8olIxKM7:TR?= M2\Fd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 10 NWHmXXRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXHSoc1QCCq MYfJR|UxRTFwODFOwG0> NYXqXm05RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
RIVA NHz3SVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXyOFghcA>? NHjuWGtKSzVy78{eNlAh|ryP MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3i3clQ5KGh? M2PJU2lEPTB;MUeuOEDPxE1? NFzXbXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
Ly 1 NFTDdoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;HO|IhcA>? MkfZTWM2OD1yLkCxJO69VQ>? NXn6WmRNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Ly 7 NGfYVYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUC3NkBp M4TZbmlEPTB;MD6wNVgh|ryP NFHOR4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
Su-DHL6 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1n4RVczKGh? M4G3TWlEPTB;MT62JO69VQ>? M1rWS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 10 NEjiSGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLV[Yk4OiCq MmDqTWM2OD1zLkKg{txO NXW3ZWRURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
RIVA MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPmO|IhcA>? M{n6WWlEPTExvK6yNEDPxE1? NYntVoxCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Su-DHL2 NEXO[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[4O|IhcA>? M3LteWlEPTB;MUGuNkDPxE1? MoXpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
U373-MAGI MULBcpRqfmm{YXygZZN{[Xl? MVuwMlI2KHSxIEigeW0> M3TnN|IhfG9iN{KgbJJ{ NWXZRYxPSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhXlOYLVegdJNmfWSxdInw[YQhUEmYLUGgUmw1NTNiaX7m[YN1\WRiaX6gbJVu[W5iVUO3N{1OSUeLIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBWPS2pYXegcIV3\WxiYYSgNE4zPSC2bzC4JJVOKGGodHXyJFIhfG9iN{KgbJJ{KGK7IIHQR3IhdWW2aH;k MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzN{K2NEc,OjdzMUeyOlA9N2F-
U373-MAGI MoHrRY51cX[rcnHsJIF{e2G7 NYC3U5NROC5{NTD0c{A5KHWP MmXBNkB1dyB5MjDodpM> NVnBd2RwSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhXlOYLVegdJNmfWSxdInw[YQhUEmYLUGgUmw1NTNiaX7m[YN1\WRiaX6gbJVu[W5iVUO3N{1OSUeLIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBo[WdibHX2[Ywh[XRiMD6yOUB1dyB6IIXNJIFnfGW{IEKgeI8hPzJiaILzJIJ6KHGSQ2KgcYV1cG:m NILZZ409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxO|I3OCd-MkexNVczPjB:L3G+

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
Survivin / Bcl-2 / p53 / c-Myc / DNMT1; 

PubMed: 26384351     


HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells.

p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; 

PubMed: 25762617     


Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations.

phospho-p38 / p38 / phospho-NFκB / NFκB; 

PubMed: 26617834     


Decitabine suppressed the phosphorylation of p38 and NF-κB.

p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; 

PubMed: 26692933     


DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments.

E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; 

PubMed: 28152502     


The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.

26384351 25762617 26617834 26692933 28152502
Immunofluorescence
DNMT1; 

PubMed: 21303982     


Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain).

E-cadherin / MMP-9; 

PubMed: 28152502     


Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC. 

21303982 28152502
Growth inhibition assay
Cell viability; 

PubMed: 26384351     


Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.

26384351
体内試験 In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
- 合併

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
細胞試験: [1]
- 合併
  • 細胞株: HL-60 and KG1a
  • 濃度: 0-500 nM
  • 反応時間: 96 hours
  • 実験の流れ: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (参考用のみ)
動物試験:[2]
- 合併
  • 動物モデル: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • 投薬量: ≤2.5 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
water
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 228.21
化学式

C8H12N4O4

CAS No. 2353-33-5
Storage powder
in solvent
別名 Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR
Smiles C1C(C(OC1N2C=NC(=NC2=O)N)CO)O

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04985656 Not yet recruiting Drug: Pevonedistat|Drug: Decitabine|Drug: Cedazuridine Myelodysplastic Syndromes (MDS) Takeda October 1 2021 Phase 2
NCT04854889 Recruiting Drug: Decitabine Refractory Aplastic Anemia Institute of Hematology & Blood Diseases Hospital April 22 2021 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Is S1200 a racemic mixture or a monomer?

  • 回答:

    S1200 is R form

DNA Methyltransferaseシグナル伝達経路

Tags: Decitabine (NSC 127716)を買う | Decitabine (NSC 127716) ic50 | Decitabine (NSC 127716)供給者 | Decitabine (NSC 127716)を購入する | Decitabine (NSC 127716)費用 | Decitabine (NSC 127716)生産者 | オーダーDecitabine (NSC 127716) | Decitabine (NSC 127716)化学構造 | Decitabine (NSC 127716)分子量 | Decitabine (NSC 127716)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID